NYSE:PFE

Pfizer Inc (PFE-N)

24.47
-0.11 (0.45%)
as of Jul 18, 2025, 8:00:00 pm Market Open.
575 watching
0

Related posts

Nervous markets await Nvidia
Investor Insights
Apr 16, 2025, 12:00 am

This summary was created by AI, based on 37 opinions in the last 12 months.

Pfizer Inc (PFE) is currently perceived as a value play in the pharmaceutical sector, with a secure dividend yield of around 6%. Experts note that while the company has a strong cash flow and a robust R&D pipeline, it has struggled to grow and deliver significant shareholder value since the COVID-19 pandemic. Acquisitions, particularly in oncology, have been under scrutiny, as some analysts believe they haven’t yet justified their costs. Overall, analysts express some caution, suggesting that there are better growth opportunities in the pharmaceutical space, yet many agree that the current stock price may present a buying opportunity for income-focused investors. With a consensus on its stable dividend, the sentiment leans towards long-term holding rather than immediate gains.

Consensus
Hold
Valuation
Undervalued

Most recent Opinions go here

Be up to date, don’t miss your chance.

WATCH

Worth taking a good, hard look at. Phenomenal yield, and he likes yield. Chart is starting to form a bit of a bottom. Low PE. Has things in the pipeline that the market's not paying for. If you're a longer-term investor, well worth sitting on it and getting rewarded while you wait for an upside pop from the drugs coming through as hoped. 

He's looking at it closely.

SELL ON STRENGTH

Laggard. Doesn't see anything in the healthcare sector that points to a turnaround in the near term. Target on the sector's back on margins. Stock's bounced over the last few weeks, use that to move on.

DON'T BUY

The problem with pharma is that their drugs all face a patent cliff. Over the last 25 years, pharma companies have tried to sustain themselves through consolidation (mergers, buying small companies). Caution: the dividend may look attractive, but that could be the result of the falling share price.

COMMENT

It needs a catalyst, like a new cancer formulation. Otherwise, you're just collecting that 6.75% dividend.

Unspecified

She likes the space but people are not investing in it. It has a low valuation and is tempting but she prefers elsewhere. It is a global leader in a crowded field. She sees 5% growth so there is some upside.

DON'T BUY

He owned it but sold. Free cash flow is not abundant and it has a lot of debt. It will take time to turn around but pays a good dividend.

BUY

Pays a 7% dividend. Something good must be coming out of their Seagen acquisition. The pipeline looks promising.

WATCH

Once upon a time, he really liked it. Beaten up for inability to bring forward a weight-loss drug; that may or may not be a realistic critique of this stock long term. Analyst community is really...just...waiting. He sold last year, not ready to come back in. Solid company, an improved oncology pipeline might be a reason to get back in.

BUY

It can bottom here. He believes in their Seagen acquisition.

BUY

Hangover from its Covid highs. Working on an obesity pill, but pulled back on it. Opportunities in the pipeline. Owned in his income growth portfolio for the yield. Despite the chart, likes it here. Fairly cheap, hopefully hitting a bottom (knock wood).

BUY

Failure in a couple of drugs. Huge research program; they will find new drugs. Outstanding stock to accumulate because, at some point, they're going to announce a new drug and the stock will pop. Yield is close to 7-8%.

DON'T BUY

Thinks dividend is safe, but may be challenged. Spent billions on acquisitions, but hasn't gained much. Not growing. Any boost to bottom line comes from cost cuts. Downhill since Covid, pipeline not strong. Better opportunities in the pharma space, such as MRK. 

HOLD

You'd have thought they'd be hit more by tariffs, as Trump hammers on that many drug components are made overseas. So the market must be thinking tariffs will benefit pharma, to explain why this name is up on such a tremendously down day. Keeping people guessing and on a knife's edge isn't a bug of the current US administration, it's a feature.

His healthcare investments focus on health management like UNH and medical devices.

DON'T BUY

It's cheap, but for a reason. Sees no growth, despite a big acquisition. Consider Merck or Amgen for perhaps more growth.

WATCH

It reports Tuesday. Their anti-cancer drugs still haven't broken up to justify the cost of acquiring them. Good news would pop shares up. Little downside now.

Showing 1 to 15 of 858 entries

Pfizer Inc(PFE-N) Rating

Ranking : 5 out of 5

Star iconStar iconStar iconStar iconStar icon

Bullish - Buy Signals / Votes : 10

Neutral - Hold Signals / Votes : 4

Bearish - Sell Signals / Votes : 10

Total Signals / Votes : 24

Stockchase rating for Pfizer Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Pfizer Inc(PFE-N) Frequently Asked Questions

What is Pfizer Inc stock symbol?

Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N

Is Pfizer Inc a buy or a sell?

In the last year, 24 stock analysts published opinions about PFE-N. 10 analysts recommended to BUY the stock. 10 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Pfizer Inc.

Is Pfizer Inc a good investment or a top pick?

Pfizer Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Pfizer Inc.

Why is Pfizer Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Pfizer Inc worth watching?

24 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.

What is Pfizer Inc stock price?

On 2025-07-18, Pfizer Inc (PFE-N) stock closed at a price of $24.47.